halotestin tablets

Drug interactions caused by competition and halotestin tablets by binding to the active centers of esterases, transforming oseltamivir phosphate in the active substance, are not covered in detail in the literature. The low degree of binding of oseltamivir and the active metabolite of protein do not suggest the presence of interactions associated with the displacement of medicines from its association with proteins.

Experiments in vitro showed that neither oseltamivir phosphate, or active metabolite are not the preferred substrate for oxidases multifunctional cytochrome  or glucuronyltransferases (cm. “Pharmacokinetics”). The formal basis for the interaction with oral contraceptives is not.

Cimetidine, a non-specific inhibitor of cytochrome  isoenzyme system, does not affect the plasma concentrations of oseltamivir and its active metabolite.

Simultaneous administration of probenecid leads to an increase in of the active metabolite is about 2 times. However, dose adjustment, while the use of probenecid is not required.

Simultaneous treatment with amoxicillin does not affect the plasma concentrations of both drugs. Simultaneous treatment with paracetamol does not affect the plasma concentrations of oseltamivir, its active metabolite, and paracetamol.

In clinical phase III trials  administered with commonly used drugs such as halotestin tabletsinhibitors (enalapril, captopril), thiazide diuretics (bendroflyuazid), antibiotics (penicillin, cephalosporins, azithromycin, erythromycin and doxycycline), blockers H 2 -receptor histamine ( ranitidine, cimetidine), beta-blockers (propranolol), xanthine (theophylline), sympathomimetics (pseudoephedrine), opiates (codeine), corticosteroids, inhaled bronchodilators and analgesics (aspirin, ibuprofen and paracetamol). Changes in the nature or frequency of adverse events was not observed in this case.

Release form and packing

Capsules

10 capsules in blister halotestin tablets.
1 blister with instruction on use is placed in a cardboard box.

Powder for suspension for oral administration               

30 g of powder for suspension for oral administration in a brown glass bottle, sealed with a screw cap, obospechivayuschey opening control and protection of children opening.
1 bottle with dosing syringe, measuring cup, and instructions for use are placed in a cardboard box.